Toxicity Profile According to Etoposide and Cytarabine Dosing in Patients with Lymphoma Receiving Autologous Stem Cell Transplantation Following BEAM Conditioning

[1]  B. Eser,et al.  A Comparison of the BEAM and MITO/MEL Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma: An Analysis of Efficiency and Treatment-Related Toxicity. , 2020, Clinical lymphoma, myeloma & leukemia.

[2]  D. Giannarelli,et al.  BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant , 2018, Bone Marrow Transplantation.

[3]  R. Houot,et al.  Rituximab after Autologous Stem‐Cell Transplantation in Mantle‐Cell Lymphoma , 2017, The New England journal of medicine.

[4]  A. Hagenbeek,et al.  Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Yannaki,et al.  Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas , 2015, Leukemia & lymphoma.

[6]  D. Coso,et al.  High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma , 2015, Leukemia & lymphoma.

[7]  N. Schmitz,et al.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Staudt,et al.  Clinical Trials and Observations , 2008 .

[9]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Pérez-Simón,et al.  Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study , 2004, Bone Marrow Transplantation.

[11]  R. Gressin,et al.  Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. , 2004, The New England journal of medicine.

[12]  M. González,et al.  BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors , 1997, Bone Marrow Transplantation.

[13]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[14]  J. Strang,et al.  Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. , 1995, Leukemia & lymphoma.

[15]  D C Linch,et al.  BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Winfield,et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.

[17]  R. Chopra,et al.  The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. , 1993, Blood.